COMMUNIQUÉS West-GlobeNewswire

CytomX Therapeutics Added to NASDAQ Biotechnology Index
18/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX ), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of [...]
Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma
18/12/2017
BERKELEY, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO ), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the first patient in its Phase 1/ [...]
Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine
18/12/2017
Data Published Online in Journal of Medicinal Chemistry Company Evaluating Potential Clinical Program for OPNT005 SANTA MONICA, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: [...]
Athenex, Inc. Added to Nasdaq Biotechnology Index
18/12/2017
BUFFALO, N.Y., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Biotricity Achieves FDA 510(k) Clearance for its Bioflux Device
18/12/2017
REDWOOD CITY, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB : BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring [...]
Pain Therapeutics Reports Positive Regulatory Meeting for REMOXY™
18/12/2017
AUSTIN, Texas, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE ), a biopharmaceutical company, today announced that it has successfully concluded a regulatory meeting with the U.S. Food and Drug [...]
Interpace Diagnostics Announces Agreement with ARUP Laboratories
18/12/2017
PARSIPPANY, N.J., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG ) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular [...]
Catalyst Biosciences Announces Acceleration of Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B
18/12/2017
Korean Ministry of Food and Drug Safety Approves Omitting Cohort 4 and Dosing Cohort 5 with Six Daily Subcutaneous Doses of Next-Generation Coagulation Factor IX Current lower doses are predicted to achieve normal [...]
Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA
18/12/2017
FRAMINGHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the [...]
EDAP's Focal One® Robotic HIFU Treatments Performed at Acibadem Hospital, Istanbul, Turkey
18/12/2017
LYON, France, December 18, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the first HIFU treatments performed at Acibadem Hospital, Istanbul, Turkey, using the Company's [...]
ICU Medical, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference
18/12/2017
SAN CLEMENTE, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI ), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care [...]
REPEAT – Cannabis Wheaton Income Corp. Announces Sustainable Growth Strategic Capital Corp. as New Wheaton Streaming Partner
18/12/2017
VANCOUVER, British Columbia, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (d/b/a Wheaton Income) (TSX.V:CBW) (" Wheaton Income " or the " Company ") is pleased to announce that it has entered into a [...]
Kura Oncology Added to Nasdaq Biotechnology Index
18/12/2017
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA ), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has [...]
Innovation Pharmaceuticals Brilacidin Oral Mucositis Program Moving Forward Based Upon Positive Anchoring Phase 2 Results and Increased Brilacidin Franchise Value
18/12/2017
BEVERLY, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today is pleased to provide an update on the developmental plan for [...]
Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer
18/12/2017
Dr. Leonard has successfully led the development and regulatory approval of breakthrough biopharmaceuticals Company’s pipeline continues to advance toward clinical development CAMBRIDGE, Mass., Dec. 18, 2017 (GLOBE [...]
Major shareholder announcement
18/12/2017
Orphazyme A/S Company announcement No. 17/2017 Major shareholder announcement Copenhagen, December 18, 2017 – With reference to company announcement no. 5/2017 dated November 16, 2017 regarding the result of the Initial [...]
Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
18/12/2017
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis [...]
Sanofi et Alnylam présentent une demande d'autorisation de mise sur le marché à l'Agence européenne des médicaments pour le patisiran dans le traitement de l'amylose héréditaire à transthyrétine
18/12/2017
Communiqué de presse Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi et Alnylam présentent une demande d'autorisation de mise sur le marché à l'Agence européenne des médicaments pour le patisiran dans le traitement de [...]
Deciphera Pharmaceuticals, Inc. Added to Russell 2000® Index
18/12/2017
WALTHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH ), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today [...]

Pages